Leniolisib-d5
Leniolisib-d5 is a deuterated labeled Leniolisib[1]. Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.
Product Specifications
Product Name Alternative
CDZ173-d5
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Isotope-Labeled Compounds; PI3K
Type
Isotope-Labeled Compounds
Related Pathways
Others; PI3K/Akt/mTOR
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Purity
98.78
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
COC1=C(C(F)(F)F)C=C(N2CC(C(N[C@H]3CCN(C(C([2H])([2H])C([2H])([2H])[2H])=O)C3)=NC=N4)=C4CC2)C=N1
Molecular Formula
C21H20D5F3N6O2
Molecular Weight
455.49
Precautions
H302, H315, H319, H335
References & Citations
[1]Hoegenauer K, et al. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med Chem Lett. 2017 Aug 25;8 (9) :975-980. |[2]Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
NTR21-A 100 µg
Anti-Rat Neurotensin receptor 2 (NTR2) IgG # 1 (aff pure)
Sign In for Pricing
View Details MBS6437612-02 5x 0.1 mL
SIRT1 (Sirtuin Type 1, SIR2L1) (MaxLight 490)
Sign In for Pricing
View Details 
ARP52178_P050-FITC 100 µL
HBXIP Antibody - N-terminal region : FITC (ARP52178_P050-FITC)
Sign In for Pricing
View Details 